YU90702A - S-metil-dihidro-ziprasidon za lečenje psihijatrijskih i okularnih oboljenja - Google Patents

S-metil-dihidro-ziprasidon za lečenje psihijatrijskih i okularnih oboljenja

Info

Publication number
YU90702A
YU90702A YU90702A YUP90702A YU90702A YU 90702 A YU90702 A YU 90702A YU 90702 A YU90702 A YU 90702A YU P90702 A YUP90702 A YU P90702A YU 90702 A YU90702 A YU 90702A
Authority
YU
Yugoslavia
Prior art keywords
disorder
disorders
anxiety
treatment
psychotic
Prior art date
Application number
YU90702A
Other languages
English (en)
Inventor
Chandra Aggarwal Prakash
Teresa Annette Smolarek
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26903852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU90702(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of YU90702A publication Critical patent/YU90702A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ovaj pronalazak se odnosi na farmaceutske preparate koji sadrze S-metil-dihidroziprasidon i upotrebu ovog jedinjenja i njegove farmaceutski prihvatljive soli za lecenje psihijatrijskih i okularnih oboljenja. Tacnije, odnosi se na upotrebu ovih jedinjenja i njegovih farmaceutski prihvatljivih soli za lecenje oboljenja ili stanja odabranih izmedju sizofrenije, stanja uznemirenosti kao sto je opste stanje uznemirenosti, panicno oboljenje, post-traumatsko oboljenje ili fobije (npr. fobija od socijalizacije, agorafobija i sl.); psihoticni napadi uznemirenosti: uznemirenost, agitacija, agresivnost, napetost ili socijalno ili emotivno povlacenje povezano sa psihozama; poremecaj psihoticnog raspolozenja kao sto je tesko depresivno oboljenje, poremecaj raspolozenja povezan sa psihoticnim oboljenjima kao sto je akutna manija ili depresija povezana sa bipolarnim oboljenjem i poremecaj raspolozenja povezan sa sizofernijom; poremeceno ponasanje povezano sa mentalnom retardacijom, autizam ili poremecaj vladanja; demencije kao sto su demencija povezana za Alzheimerovim oboljenjem; disineziaze izazvane upotrebom opojnih sredstava i zasnovane na neurodegenerizaciji, obsesivno kompulsivno oboljenje; Tourett-ov sindrom, glaukoma i ishemijska retinopatija.
YU90702A 2000-06-02 2001-05-28 S-metil-dihidro-ziprasidon za lečenje psihijatrijskih i okularnih oboljenja YU90702A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20913600P 2000-06-02 2000-06-02
US21217200P 2000-06-16 2000-06-16

Publications (1)

Publication Number Publication Date
YU90702A true YU90702A (sh) 2005-11-28

Family

ID=26903852

Family Applications (1)

Application Number Title Priority Date Filing Date
YU90702A YU90702A (sh) 2000-06-02 2001-05-28 S-metil-dihidro-ziprasidon za lečenje psihijatrijskih i okularnih oboljenja

Country Status (44)

Country Link
US (1) US20060287336A1 (sh)
EP (3) EP1286672B1 (sh)
JP (2) JP2003534381A (sh)
KR (1) KR20030007824A (sh)
CN (1) CN1431901A (sh)
AP (2) AP1831A (sh)
AR (1) AR028937A1 (sh)
AT (3) ATE343387T1 (sh)
AU (1) AU2001258690A1 (sh)
BG (1) BG107267A (sh)
BR (1) BR0111271A (sh)
CA (1) CA2410618A1 (sh)
CY (1) CY1105992T1 (sh)
CZ (1) CZ20023860A3 (sh)
DE (3) DE60124093D1 (sh)
DK (1) DK1468686T3 (sh)
DO (1) DOP2001000181A (sh)
EA (1) EA007068B1 (sh)
EC (1) ECSP024369A (sh)
EE (1) EE200200670A (sh)
ES (1) ES2277170T3 (sh)
GE (1) GEP20053512B (sh)
HN (1) HN2001000119A (sh)
HR (1) HRP20020953A2 (sh)
HU (1) HUP0301747A2 (sh)
IL (2) IL152782A0 (sh)
IS (1) IS6619A (sh)
MA (1) MA26908A1 (sh)
MX (1) MXPA02011862A (sh)
NO (1) NO325077B1 (sh)
NZ (1) NZ551012A (sh)
OA (1) OA12267A (sh)
PA (1) PA8518301A1 (sh)
PE (1) PE20011329A1 (sh)
PL (1) PL365576A1 (sh)
PT (2) PT1698338E (sh)
SI (1) SI1468686T1 (sh)
SK (1) SK16622002A3 (sh)
SV (1) SV2002000473A (sh)
UA (1) UA79425C2 (sh)
UY (1) UY26742A1 (sh)
WO (1) WO2001091756A2 (sh)
YU (1) YU90702A (sh)
ZA (1) ZA200209665B (sh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003296991A1 (en) 2002-12-13 2004-07-09 Regents Of The University Of Minnesota Scleral depressor
US7667037B2 (en) 2003-10-24 2010-02-23 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
JP2012174228A (ja) * 2011-02-24 2012-09-10 Kyocera Corp プログラム保護装置および通信装置
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US9981041B2 (en) * 2016-08-23 2018-05-29 Ira Jason Salzman Ophthalmic lubricating spray

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW491847B (en) * 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
KR100333214B1 (ko) * 1996-05-07 2002-06-20 디. 제이. 우드, 스피겔 알렌 제이 5-(2-(4-(1,2-벤즈이소티아졸-3-일)-1-피페라지닐)에틸)-6-클로로-1,3-디하이드로-2(1에이치)인돌-2-온(지프라시돈)의메실레이트트리하이드레이트염,이의제조방법및도파민디2길항물질로서의이의용도
PT985414E (pt) * 1998-05-26 2004-01-30 Pfizer Prod Inc Metodo de tratamento de glaucoma e retinopatia isquemica
CA2363942A1 (en) * 1999-04-06 2000-10-12 Sepracor Inc. Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites

Also Published As

Publication number Publication date
DE60133596D1 (de) 2008-05-21
DE60124791D1 (de) 2007-01-04
EP1286672B1 (en) 2006-10-25
EP1286672A2 (en) 2003-03-05
PL365576A1 (en) 2005-01-10
AP1747A (en) 2007-05-31
ATE391507T1 (de) 2008-04-15
EA007068B1 (ru) 2006-06-30
DE60124093D1 (de) 2006-12-07
WO2001091756A2 (en) 2001-12-06
ATE345818T1 (de) 2006-12-15
ATE343387T1 (de) 2006-11-15
SI1468686T1 (sl) 2007-04-30
SK16622002A3 (sk) 2004-07-07
AP2005003272A0 (en) 2005-03-31
UY26742A1 (es) 2001-12-28
MXPA02011862A (es) 2003-04-10
JP2003534381A (ja) 2003-11-18
CY1105992T1 (el) 2011-04-06
EP1698338B1 (en) 2008-04-09
OA12267A (en) 2004-01-20
CA2410618A1 (en) 2001-12-06
PE20011329A1 (es) 2002-01-15
CN1431901A (zh) 2003-07-23
HRP20020953A2 (en) 2005-02-28
EP1698338A3 (en) 2006-09-20
IL152782A (en) 2007-10-31
PA8518301A1 (es) 2002-09-17
GEP20053512B (en) 2005-05-10
EP1468686A2 (en) 2004-10-20
PT1468686E (pt) 2007-01-31
AR028937A1 (es) 2003-05-28
NO325077B1 (no) 2008-01-28
NO20025760D0 (no) 2002-11-29
IS6619A (is) 2002-11-14
AP1831A (en) 2008-02-26
NO20025760L (no) 2003-01-15
US20060287336A1 (en) 2006-12-21
EA200201168A1 (ru) 2003-06-26
HUP0301747A2 (hu) 2003-09-29
ES2277170T3 (es) 2007-07-01
BR0111271A (pt) 2003-06-10
AU2001258690A1 (en) 2001-12-11
EP1468686B1 (en) 2006-11-22
HN2001000119A (es) 2001-09-11
EP1468686A3 (en) 2004-12-01
EP1698338A2 (en) 2006-09-06
BG107267A (bg) 2003-06-30
PT1698338E (pt) 2008-06-03
ZA200209665B (en) 2003-11-28
KR20030007824A (ko) 2003-01-23
JP2008056700A (ja) 2008-03-13
MA26908A1 (fr) 2004-12-20
DOP2001000181A (es) 2002-04-15
DK1468686T3 (da) 2007-03-12
EE200200670A (et) 2004-08-16
ECSP024369A (es) 2003-02-06
NZ551012A (en) 2008-04-30
SV2002000473A (es) 2002-10-24
WO2001091756A3 (en) 2002-09-26
UA79425C2 (en) 2007-06-25
CZ20023860A3 (cs) 2004-01-14
IL152782A0 (en) 2003-06-24
DE60124791T2 (de) 2007-09-13

Similar Documents

Publication Publication Date Title
CA2256227A1 (en) Method of treating psychiatric conditions
BR9914293A (pt) Processo para a purificação de 1,3-propanodiol
CO5611138A2 (es) Composicion de ziprasidona y controles sinteticos
ATE492279T1 (de) Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen
MA28515B1 (fr) Inhibiteurs de gsk-3
MX2007012883A (es) Derivados de dihidrobenzofurano y usos de los mismos.
MXPA05012391A (es) Tratamiento de trastornos psicoticos y depresivos.
AR044337A1 (es) Procedimiento para potenciar la cognicion usando ziprasidona
BG105112A (en) Agents with antidepressive effect
EP2561889A3 (en) Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
CY1105992T1 (el) Σ-μεθυλ-διυδρο-ζιπρασιδονη για τη θepαπευτικη αγωγη ψυχιατρικων διαταραχων
EA200801302A1 (ru) Композиции и способы лечения нарушений цнс
WO2003105781A3 (en) OPHTHALMIC COMPOSITIONS FOR TREATING EYE HYPERTENSION
WO2003057213A3 (en) Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
ATE552251T1 (de) Thiophen- und furanverbindungen
WO2008018639A3 (en) Glycine transporter inhibitor
ATE247630T1 (de) Verfahren zur herstellung von n,n'-bis,2,3- dihydroxypropyl)-5-((hydroxyacetyl)methylamino) 2,4,6-triiodo-1,3-benzenedicarboxamide
MY129575A (en) Methods, kits and compositions for using pyrrole derivatives againts anxiety
BR0202323B1 (pt) liga nodular de ferro fundido, bem como processo para produtos de ferro fundido com deformabilidade plástica.
MX2008001200A (es) Derivados de acido 2-hidroxi-propionico y derivados de 3-hidroxi-benzofura-2-ona con afinidad para el receptor gaba-b.
DE69533214D1 (de) 2,3-Dihydro-1H-isoindolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Hemmer der Serotoninwiederaufnahme
BR0317644A (pt) Cilopentil glutaramidas e seu uso como inibidores de endo-peptidase neutros
BR9915572A (pt) Processo de tratamento de doença de célula falciforme e talassemia
WO2006013546A3 (en) Process for the preparation of pure galantamine